Glyn was appointed Chairman of MitoRx Therapeutics in February 2022. He is also non-executive director at OxSonics & Orthoson. Glyn previously served as CEO of Summit Therapeutics plc 2012-2020 where he restructured the business, took the company through a NASDAQ listing and took its Duchenne muscular dystrophy  (DMD) clinical development program through late-stage trials. Prior to joining Summit, he served as interim CEO of the BioIndustry Association (BIA), and as CEO at Antisoma plc, a biotech company specialising in the development of novel drugs for the treatment of cancer from 1998 to 2011. Glyn was awarded an MBE for his services to the biotechnology industry in 2006.